Translate this page into:
Quantitative fibrinogen disorders: A retrospective study from a tertiary care centre in India
For correspondence: Dr Mili Jain, Department of Pathology, King George’s Medical University, Lucknow 226 003, Uttar Pradesh, India e-mail: milijain786@gmail.com
-
Received: ,
Accepted: ,
How to cite this article: Jain M, Shukla H, Kushwaha R, Mishra S, Yadav G, Verma N. Quantitative fibrinogen disorders: A retrospective study from a tertiary care centre in India. Indian J Med Res. 2026;163:687-91. doi: 10.25259/IJMR_2494_2025
Abstract
Background and objectives
Congenital fibrinogen disorders encompass both quantitative and qualitative abnormalities of fibrinogen, characterised by variable bleeding or thrombotic tendencies. Due to their rarity and varied presentations, delays in diagnosis are common, which can significantly impact patient outcomes. This study was conducted to describe the clinical and demographic profiles of patients with congenital quantitative fibrinogen disorders over a 20-year period (2003-2024) at a tertiary care centre.
Methods
A retrospective analysis was conducted using laboratory records to identify 17 patients with quantitative fibrinogen disorders, characterised by prolonged prothrombin time (PT), activated partial thromboplastin time (APTT), and undetectable or low fibrinogen levels. Only 10 out of 17 patients could be contacted for follow up. The clinical presentation, including scoring of bleeding symptoms using the International Society on Thrombosis and Haemostasis - Bleeding Assessment Tool (ISTH-BAT), as well as demographic variables such as age of onset, first visit to our hospital, and diagnostic delays, were recorded. Treatment and follow up data were recorded.
Results
Majority of patients showed symptoms in the neonatal period, with umbilical bleeding as the most common initial manifestation, followed by post-traumatic and cutaneous bleeding. Despite early symptom onset, a median diagnostic delay of four years was observed. Seven cases were under regular follow up with on-demand therapy. Three patients died during follow up. Most of the cases received fresh frozen plasma.
Interpretation and conclusions
This study describes the clinical profile of quantitative fibrinogen disorders and emphasises the importance of increased awareness, early diagnosis, and standardised management in these patients. Given the significant risk of bleeding, proactive measures such as patient education and close monitoring are crucial.
Keywords
Afibrinogenemia
Coagulation disorder
Fibrinogen deficiency
Neonatal period
Umbilical stump bleeding
Fibrinogen plays a vital role in normal haemostasis by promoting platelet aggregation, clot formation and fibrinolysis. The disease-causing genetic variants affecting fibrinogen synthesis result in a range of bleeding or occasionally thrombotic phenotypes. Inherited disorders of fibrinogen either affect the quantity (that is, afibrinogenemia with very low or absent measurable fibrinogen and hypofibrinogenemia with reduced levels) or the quality (dysfibrinogenemia where fibrinogen levels are normal but are functionally abnormal) or both.1-3
Fibrinogen is a glycoprotein synthesised in the liver. It is a hexamer composed of two copies each of three polypeptide chains, coded by three different genes (FGA, FGB, FGG) on the short arm of chromosome 4. Congenital afibrinogenemia is a rare condition, with an estimated worldwide prevalence of 1-2 cases per million. 4 The frequency of hypofibrinogenemia is believed to be higher, although precise data are not available, as a large proportion of these patients are asymptomatic. There is extreme allelic heterogeneity in these disorders. Clinical features vary, ranging from being asymptomatic to life-threatening bleeding. Afibrinogenemia primarily presents with bleeding in several tissues, including the umbilical cord, skin, muscles, joints, and the central nervous system. Patients with hypofibrinogenemia have a lower risk compared to those with afibrinogenemia. Thrombosis in arterial/venous circulation is also commonly observed. Additionally, features of poor wound healing, painful bone cysts, and spontaneous splenic rupture, may also occur. 5,6
These disorders are often misdiagnosed and underreported. The data reported from Indian patients is primarily in the form of case reports and case series from tertiary centres. We describe our experience with congenital quantitative fibrinogen deficiency patients diagnosed at our centre over a period of 20 years.
Methods
This retrospective analysis was undertaken by the department of Pathology, King George’s Medical University, Lucknow, Uttar Pradesh, India. The study was conducted after obtaining ethical approval from the Institutional ethics committee. We conducted a retrospective analysis of cases diagnosed with quantitative fibrinogen disorders over a 20-year period at our tertiary care centre.
Laboratory workup
A total of 17 patients with a diagnosis of afibrinogenemia/hypofibrinogenemia were included in this study. Diagnosis was confirmed by the complete or partial absence of fibrinogen, infinitely prolonged Prothrombin time (PT) and activated partial thromboplastin time (APTT). In patients who have received blood transfusions or blood components, derangements in coagulation tests may be transiently masked. The effect lasts depending on the half-life of the factors in the transfused product; hence, for all suspected cases of bleeding disorders, we repeated the testing after 7 days of any transfusion.
The clot-based assays for APTT and PT were performed manually until 2015 using ACTIN FSL (Siemens, Germany) for APTT and NeoPTimal (Stago, France) for PT, respectively. Following this, we conducted testing on the fully automated coagulometer STA Satellite and STA Compact (Stago, France). PT and APTT were measured using NeoPTimal and CK Prest (Stago, France), respectively. Urea clot lysis was done to rule out factor XIII deficiency if indicated.
Quantitative measurement of fibrinogen activity was performed using the STA liquid Fib kit (Stago, France), based on the Clauss clotting method combined with mechanical clot detection. The working range for the kit is 40 mg/dL to 1200 mg/dL. The linear range of the assay is 100-800 mg/dL; the lower limit of detection can be extended up to 40 mg/dL by using appropriate dilutions. A fibrinogen antigen assay to further differentiate hypofibrinogenemia from afibrinogenemia was not done. The normal plasma fibrinogen level in the adult population ranges from 200 to 400 mg/dL.
Demographic and clinical data
The study variables, including age, gender, clinical symptoms, bleeding profile, area of residence and treatment received, were obtained from the laboratory and clinical case records. For all patients, a three-generation pedigree chart was made while recording the history. The bleeding phenotype was scored with the International Society on Thrombosis and Haemostasis bleeding assessment tool (ISTH-BAT).7-9 For patients enrolled before 2020, the ISTH-BAT score was calculated retrospectively based on case record forms; patients were contacted by telephone if required. From 2020 onwards, the ISTH-BAT scores were recorded during the filling of case record details for laboratory workup at our centre. The ISTH-BAT includes 14 questions regarding clinical symptoms, and each bleeding symptom can be scored on a scale of 0 to 4. The cut-off total score is considered abnormal, indicating bleeding tendency according to age and gender. That is, values equal to or greater than 3, 4, and 6 for children, adult males, and adult females, respectively, are considered abnormal. Out of 17 patients, 10 patients could be contacted for follow up status.
Results
The retrospective data of patients diagnosed with quantitative fibrinogen disorders at a tertiary care centre in Northern India over a period of 20 years (2003-2024) are presented. The majority (65%) of the cases were diagnosed in the last 10 years. Diagnosis of all cases was made based on prolonged PT and APTT tests, as well as undetectable fibrinogen levels. All patients presented during the neonatal period, with a median age of onset of symptoms of 4 days (1-30 days). The median age at first visit to the hospital for an appropriate diagnostic workup was 4 years (4 months-12 years). A delay in visiting the hospital for appropriate diagnostic workup was noted in most cases, with a median delay of 4 years (4 months-12 years). Only three cases received a timely diagnosis, two of which belonged to the same city. The cases visiting our centre come from distant rural and urban areas of the State (urban to rural ratio 9:8) ( Figure). The median distance of visit for patients was 130 kilometres (4.5 km - 403 km). The delay in diagnosis for rural cases was higher compared to urban cases (median was 6 years vs. 1.5 years). The literacy status of family members (primary education vs. illiterate) did not vary between rural and urban cases. The cases were distributed among both genders, with a male-to-female ratio of 10:7. Siblings with a history of a similar illness were noted in 6 out of 17 patients (35%). Nearly half of the cases (8/17) resulted from a consanguineous marriage. Consanguinity was primarily observed in Muslim patients.
![Uttar Pradesh State map, showing distribution of cases originating from various districts. Cases 1-4: Lucknow, Case 5: Barabanki, Case 6-7: Sitapur, Case 8: Gonda, Case 9: Ayodhya, Case 10: Basti, Case 11-12: Gorakhpur, Case 13: Banda, Case 14: Hardoi, Case 15: Saharanpur, Case 16: Budaun, Case 17: Bijnor [Source: the map was adopted from online source (Wikimedia) and edited on Adobe Stock (https://stock.adobe.com/search?k=uttar+pradesh+map)].](/content/175/2026/163/5/img/IJMR-163-5-687-g1.png)
Bleeding symptoms
Umbilical stump bleeding was the most common presenting symptom, observed in all the cases. The other common presentation included post-traumatic bleeding (n=15) and cutaneous bleeds (n=14). Other patterns of bleeding included oral bleeding (n=6), hemarthrosis (n=3), epistaxis (n=2), muscle hematoma (n=1), menorrhagia (n=1), and cranial bleeding (n=1). Complaints of gastrointestinal bleed, haematuria, bleed following tooth extraction, post-surgery bleed, and post-partum bleed were not recorded in our cases. The bleeding symptoms of all patients were scored on the ISTH-BAT scale. The median score was 7 (range 4-10).
Treatment
Ten patients could be traced for follow up at the time of drafting this manuscript. Of these, seven were under regular follow-up with on-demand therapy. Three of these patients died following cerebral bleed, post-traumatic and nasal bleed, respectively. Seven cases could not be contacted for follow up.
Patients had visited health facilities of variable capacities and received transfusions accordingly after the diagnosis. Almost all were treated with fresh-frozen plasma or cryoprecipitate, as available. Post treatment fibrinogen levels were not evaluated, control of bleeding was considered as response. The initial transfusion support consisted of packed red blood cells (8/17), random donor platelets (4/17), and whole blood (2/17).
Discussion
As per the International Society of Thrombosis and Haemostasis, quantitative fibrinogen deficiency may be classified as mild hypofibrinogenemia (lower limit of normal to 1g/L), moderate hypofibrinogenemia (0.9-0.5g/L), severe hypofibrinogenemia (0.5-0.1g/L) and afibrinogenemia (unmeasurable fibrinogen level <0.1g/L). 4 Clinically, bleeding episodes are the main symptoms in afibrinogenemia, whereas in hypofibrinogenemia, cases are more often asymptomatic. Although cases often present early in life, a delay in timely diagnosis and intervention is frequently observed. Comparing the data from two decades, we can observe that the number of diagnosed cases nearly doubled in the last decade. This could be attributed to the improved approachability of patients to the diagnostic facility. However, patient awareness does not seem to have improved, as the median delay in diagnosis did not show a significant difference. The higher median delay observed in cases from rural areas again highlights the lack of patient awareness.
Most cases presented in the neonatal period, as previously reported. 3,6 However, the median age of presentation to our hospital for complete diagnostic work is lower as compared to previous Indian reports. 5,6,10 The registered cases involve both genders; however, a male predominance was observed in our study, consistent with previous reports. 5 Other Indian studies have shown a female predominance. 10 History of consanguineous marriage has been reported in all previous Indian studies with variable proportion (ranging from 33 to 74%) attributable to the regional social and cultural practices 2,3,5,6 similar to our study.
A family history of an affected sibling was observed in nearly one-third of the cases in our data, which aligns with previous studies (ranging from 25 to 42%). None of the parents was affected, pointing towards the recessive pattern of inheritance. Additionally, cases from both genders can be attributed to an autosomal recessive inheritance pattern in our study group. According to current practice, when dealing with patients exhibiting bleeding symptoms, the use of a bleeding assessment tool is recommended. We have tried to score all our cases according to the ISHT-BAT score. As previously proposed, all our cases belong to a severe bleeding phenotype. 7
Umbilical bleeding was observed uniformly in all cases. The reported literature shows a highly variable prevalence of umbilical cord bleed (12.5% to 62%). 5,6,10 In many of the studies, post-traumatic bleed has been reported as the most common symptom (46% to 100%). 5,6,10 In our study, it was the second most common symptom, followed by cutaneous bleeding. Mucosal bleed in the form of gum bleeding and epistaxis was observed in a proportion comparable to previous reports. Muscle hematoma was observed in a single case (6%) in our study, much higher prevalence has been previously reported. 5,6,10 We did not observe post-surgical, gastrointestinal bleeding or delayed wound healing, although these symptoms have been reported in varying proportions in previous studies. Menorrhagia has been reported in cases of the reproductive age group, as per the previous reports. 5,6 We had a single case of a female in the reproductive age group, who was symptomatic for menorrhagia. As our cases comprised the paediatric age group, we could not evaluate for post-partum haemorrhage and recurrent abortion.
The study data have limitations in not categorising cases as afibrinogenemia and hypofibrinogenemia, as we have not evaluated fibrinogen antigen levels. Our data lacks genetic information that could have contributed to the correlation between genotype and phenotype. Although we evaluated retrospective cases over a two-decade period, the overall sample size may still be limited, which could affect the generalisability of our findings. As the follow-up data remains incomplete, we cannot fully comprehend treatment response, prognosis, and symptoms in later life, including thrombotic episodes. The possibility of recall bias in symptom scoring cannot be ruled out.
Overall, this study presents the demographic and clinical profiles of quantitative fibrinogen deficiency diagnosed over 20 years. A point of significant concern is the diagnostic delay these patients suffer due to a lack of appropriate testing facilities and a diagnostic approach that is not followed. The rural population bears the brunt of these pitfalls in our healthcare facilities; they often need to travel long distances for an appropriate diagnosis, which is frequently delayed. Appropriate screening tests should be done either manually or on automated analysers in patients suspected of bleeding disorders to differentiate the rare bleeding disorders from haemophilia. Our study incorporates the standardisation of bleeding symptoms assessment through the ISHT-BAT scoring system, a practice often overlooked in previous studies. This systemic approach not only enhances the reliability of symptom reporting but also facilitates a clearer understanding of bleeding phenotype in affected patients.
The ongoing need for lifelong follow up and appropriate management of patients is evident, with a significant proportion actively engaged in treatment. While fresh-frozen plasma remains the primary therapeutic option, our findings highlight the need to improve access to advanced treatments.
Author contributions
MJ, HS: Data collection, compilation, analysis, manuscript writing; RK, SM, GY: Interpretation of laboratory results, manuscript writing; NV: Patient management, manuscript writing All authors have read and approve the final printed version of the manuscript.
Financial support and sponsorship
The study received funding from Institutional funds for the procurement of consumables (reagents and kits).
Conflicts of Interest
None.
Use of Artificial Intelligence (AI)-Assisted Technology for manuscript preparation
The authors confirm that there was no use of AI-assisted technology for assisting in the writing of the manuscript and no images were manipulated using AI.
References
- Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost.. 2012;10:1938-43.
- [CrossRef] [PubMed] [Google Scholar]
- Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia. Blood.. 2021;137:3127-36.
- [CrossRef] [PubMed] [Google Scholar]
- Congenital afibrinogenemia and hypofibrinogenemia: Laboratory and genetic testing in rare bleeding disorders with life-threatening clinical manifestations and challenging management. Diagnostics (Basel).. 2021;11:2140.
- [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
- Rare coagulation factor deficiencies: A countrywide screening data from India. Haemophilia.. 2014;20:575-81.
- [CrossRef] [PubMed] [Google Scholar]
- Molecular basis of quantitative fibrinogen disorders in 27 patients from India. Haemophilia.. 2013;19:611-8.
- [CrossRef] [PubMed] [Google Scholar]
- Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: Results from the European network of rare bleeding disorders. J Thromb Haemost.. 2012;10:615-21.
- [CrossRef] [PubMed] [Google Scholar]
- ISTH-BAT/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH-BAT/SSC bleeding assessment tool: Astandardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost.. 2010;8:2063-65.
- [Google Scholar]
- Normal range of bleeding scores for the ISTH-BAT: Adult and pediatric data from the merging project. Haemophilia.. 2014;20:831-5.
- [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
- Correlating clinical manifestations with factor levels in rare bleeding disorders: A report from Southern India. Haemophilia.. 2012;18:e195-200.
- [CrossRef] [PubMed] [Google Scholar]
